Opportunities in precision psychiatry using PET neuroimaging in psychosis

Neurobiol Dis. 2019 Nov:131:104428. doi: 10.1016/j.nbd.2019.03.016. Epub 2019 Mar 20.

Abstract

With the movement toward precision medicine in healthcare, recent studies of individuals with psychosis have begun to explore positron emission tomography (PET) as a tool to test for biochemical signatures that may distinguish subtypes of psychosis that guide subtype-specific therapeutic interventions. This review presents selected PET findings that exemplify early promise in using molecular imaging to predict treatment response, provide rationale for new therapeutic targets, and monitor target engagement in biomarker-defined subtypes of psychosis. PET data, among other data types, may prove useful in the scientific pursuit of identifying precision strategies to improve clinical outcomes for individuals with psychosis.

Keywords: Dopamine; Neuroimmunity; PET imaging; Precision medicine; Psychosis; alpha7 nicotinic acetylcholine receptor.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Brain / diagnostic imaging
  • Humans
  • Molecular Imaging / methods
  • Molecular Imaging / trends
  • Neuroimaging / methods*
  • Neuroimaging / trends
  • Positron-Emission Tomography / methods*
  • Positron-Emission Tomography / trends
  • Precision Medicine / methods*
  • Precision Medicine / trends
  • Psychiatry / methods*
  • Psychiatry / trends
  • Psychotic Disorders / diagnostic imaging*